SENORES PHARMACEUTICALS L (SENORES) - Total Liabilities
Based on the latest financial reports, SENORES PHARMACEUTICALS L (SENORES) has total liabilities worth Rs4.54 Billion INR (≈ $49.07 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SENORES PHARMACEUTICALS L (SENORES) net asset momentum to track the company's year-over-year net asset growth rate.
SENORES PHARMACEUTICALS L - Total Liabilities Trend (2022–2025)
This chart illustrates how SENORES PHARMACEUTICALS L's total liabilities have evolved over time, based on quarterly financial data. See SENORES PHARMACEUTICALS L (SENORES) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
SENORES PHARMACEUTICALS L Competitors by Total Liabilities
The table below lists competitors of SENORES PHARMACEUTICALS L ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Groupon Inc
NASDAQ:GRPN
|
USA | $658.33 Million |
|
Lg Electronics Pref
KO:066575
|
Korea | ₩40.25 Trillion |
|
ESGL Holdings Limited
NASDAQ:OIO
|
USA | $12.20 Million |
|
Guangdong Lvtong New Energy Electric Vehicle Technology Co. Ltd. Cl A
SHE:301322
|
China | CN¥937.50 Million |
|
Global Mixed-Mode Technology Inc
TW:8081
|
Taiwan | NT$3.68 Billion |
|
Shanghai Shenda Co Ltd
SHG:600626
|
China | CN¥6.51 Billion |
|
Suntront Tech
SHE:300259
|
China | CN¥619.42 Million |
|
Algoma Central Corporation
TO:ALC
|
Canada | CA$762.36 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down SENORES PHARMACEUTICALS L's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SENORES PHARMACEUTICALS L stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SENORES PHARMACEUTICALS L's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SENORES PHARMACEUTICALS L (2022–2025)
The table below shows the annual total liabilities of SENORES PHARMACEUTICALS L from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs50.70 Million ≈ $548.31K |
-98.70% |
| 2024-03-31 | Rs3.90 Billion ≈ $42.20 Million |
+356.05% |
| 2023-03-31 | Rs855.54 Million ≈ $9.25 Million |
+279.20% |
| 2022-03-31 | Rs225.62 Million ≈ $2.44 Million |
-- |
About SENORES PHARMACEUTICALS L
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, ne… Read more